283 related articles for article (PubMed ID: 26588924)
21. Absorption, metabolism, and excretion of oral ¹⁴C radiolabeled ibrutinib: an open-label, phase I, single-dose study in healthy men.
Scheers E; Leclercq L; de Jong J; Bode N; Bockx M; Laenen A; Cuyckens F; Skee D; Murphy J; Sukbuntherng J; Mannens G
Drug Metab Dispos; 2015 Feb; 43(2):289-97. PubMed ID: 25488930
[TBL] [Abstract][Full Text] [Related]
22. A Phase 1b/2 Study of the Bruton Tyrosine Kinase Inhibitor Ibrutinib and the PD-L1 Inhibitor Durvalumab in Patients with Pretreated Solid Tumors.
Hong D; Rasco D; Veeder M; Luke JJ; Chandler J; Balmanoukian A; George TJ; Munster P; Berlin JD; Gutierrez M; Mita A; Wakelee H; Samakoglu S; Guan S; Dimery I; Graef T; Borazanci E
Oncology; 2019; 97(2):102-111. PubMed ID: 31230047
[TBL] [Abstract][Full Text] [Related]
23. Pirtobrutinib in relapsed or refractory B-cell malignancies (BRUIN): a phase 1/2 study.
Mato AR; Shah NN; Jurczak W; Cheah CY; Pagel JM; Woyach JA; Fakhri B; Eyre TA; Lamanna N; Patel MR; Alencar A; Lech-Maranda E; Wierda WG; Coombs CC; Gerson JN; Ghia P; Le Gouill S; Lewis DJ; Sundaram S; Cohen JB; Flinn IW; Tam CS; Barve MA; Kuss B; Taylor J; Abdel-Wahab O; Schuster SJ; Palomba ML; Lewis KL; Roeker LE; Davids MS; Tan XN; Fenske TS; Wallin J; Tsai DE; Ku NC; Zhu E; Chen J; Yin M; Nair B; Ebata K; Marella N; Brown JR; Wang M
Lancet; 2021 Mar; 397(10277):892-901. PubMed ID: 33676628
[TBL] [Abstract][Full Text] [Related]
24. Combination of ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for treatment-naive patients with CD20-positive B-cell non-Hodgkin lymphoma: a non-randomised, phase 1b study.
Younes A; Thieblemont C; Morschhauser F; Flinn I; Friedberg JW; Amorim S; Hivert B; Westin J; Vermeulen J; Bandyopadhyay N; de Vries R; Balasubramanian S; Hellemans P; Smit JW; Fourneau N; Oki Y
Lancet Oncol; 2014 Aug; 15(9):1019-26. PubMed ID: 25042202
[TBL] [Abstract][Full Text] [Related]
25. Impact of ibrutinib dose adherence on therapeutic efficacy in patients with previously treated CLL/SLL.
Barr PM; Brown JR; Hillmen P; O'Brien S; Barrientos JC; Reddy NM; Coutre S; Mulligan SP; Jaeger U; Furman RR; Cymbalista F; Montillo M; Dearden C; Robak T; Moreno C; Pagel JM; Burger JA; Suzuki S; Sukbuntherng J; Cole G; James DF; Byrd JC
Blood; 2017 May; 129(19):2612-2615. PubMed ID: 28373262
[TBL] [Abstract][Full Text] [Related]
26. Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience.
O'Brien S; Furman RR; Coutre S; Flinn IW; Burger JA; Blum K; Sharman J; Wierda W; Jones J; Zhao W; Heerema NA; Johnson AJ; Luan Y; James DF; Chu AD; Byrd JC
Blood; 2018 Apr; 131(17):1910-1919. PubMed ID: 29437592
[TBL] [Abstract][Full Text] [Related]
27. A pilot study of lower doses of ibrutinib in patients with chronic lymphocytic leukemia.
Chen LS; Bose P; Cruz ND; Jiang Y; Wu Q; Thompson PA; Feng S; Kroll MH; Qiao W; Huang X; Jain N; Wierda WG; Keating MJ; Gandhi V
Blood; 2018 Nov; 132(21):2249-2259. PubMed ID: 30254130
[TBL] [Abstract][Full Text] [Related]
28. Ibrutinib for the treatment of chronic lymphocytic leukemia and mantle cell lymphoma.
McDermott J; Jimeno A
Drugs Today (Barc); 2014 Apr; 50(4):291-300. PubMed ID: 24918646
[TBL] [Abstract][Full Text] [Related]
29. The safety of Bruton's tyrosine kinase inhibitors for the treatment of chronic lymphocytic leukemia.
Tran PN; O'Brien S
Expert Opin Drug Saf; 2017 Sep; 16(9):1079-1088. PubMed ID: 28627951
[TBL] [Abstract][Full Text] [Related]
30. Umbralisib in combination with ibrutinib in patients with relapsed or refractory chronic lymphocytic leukaemia or mantle cell lymphoma: a multicentre phase 1-1b study.
Davids MS; Kim HT; Nicotra A; Savell A; Francoeur K; Hellman JM; Bazemore J; Miskin HP; Sportelli P; Stampleman L; Maegawa R; Rueter J; Boruchov AM; Arnason JE; Jacobson CA; Jacobsen ED; Fisher DC; Brown JR;
Lancet Haematol; 2019 Jan; 6(1):e38-e47. PubMed ID: 30558987
[TBL] [Abstract][Full Text] [Related]
31. Ibrutinib combined with bendamustine and rituximab compared with placebo, bendamustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study.
Chanan-Khan A; Cramer P; Demirkan F; Fraser G; Silva RS; Grosicki S; Pristupa A; Janssens A; Mayer J; Bartlett NL; Dilhuydy MS; Pylypenko H; Loscertales J; Avigdor A; Rule S; Villa D; Samoilova O; Panagiotidis P; Goy A; Mato A; Pavlovsky MA; Karlsson C; Mahler M; Salman M; Sun S; Phelps C; Balasubramanian S; Howes A; Hallek M;
Lancet Oncol; 2016 Feb; 17(2):200-211. PubMed ID: 26655421
[TBL] [Abstract][Full Text] [Related]
32. The HELIOS trial protocol: a phase III study of ibrutinib in combination with bendamustine and rituximab in relapsed/refractory chronic lymphocytic leukemia.
Hallek M; Kay NE; Osterborg A; Chanan-Khan AA; Mahler M; Salman M; Wan Y; Sun S; Zhuang SH; Howes A
Future Oncol; 2015; 11(1):51-9. PubMed ID: 24901734
[TBL] [Abstract][Full Text] [Related]
33. Bruton's tyrosine kinase inhibitors: first and second generation agents for patients with Chronic Lymphocytic Leukemia (CLL).
Thompson PA; Burger JA
Expert Opin Investig Drugs; 2018 Jan; 27(1):31-42. PubMed ID: 29125406
[TBL] [Abstract][Full Text] [Related]
34. Extended Treatment with Single-Agent Ibrutinib at the 420 mg Dose Leads to Durable Responses in Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma.
Coutré SE; Furman RR; Flinn IW; Burger JA; Blum K; Sharman J; Jones J; Wierda W; Zhao W; Heerema NA; Johnson AJ; Tran A; Zhou C; Bilotti E; James DF; Byrd JC; O'Brien S
Clin Cancer Res; 2017 Mar; 23(5):1149-1155. PubMed ID: 28073846
[No Abstract] [Full Text] [Related]
35. Analysis of Efficacy and Tolerability of Bruton Tyrosine Kinase Inhibitor Ibrutinib in Various B-cell Malignancies in the General Community: A Single-center Experience.
Ali N; Malik F; Jafri SIM; Naglak M; Sundermeyer M; Pickens PV
Clin Lymphoma Myeloma Leuk; 2017 Jul; 17S():S53-S61. PubMed ID: 28760303
[TBL] [Abstract][Full Text] [Related]
36. Single-agent ibrutinib in relapsed or refractory follicular lymphoma: a phase 2 consortium trial.
Bartlett NL; Costello BA; LaPlant BR; Ansell SM; Kuruvilla JG; Reeder CB; Thye LS; Anderson DM; Krysiak K; Ramirez C; Qi J; Siegel BA; Griffith M; Griffith OL; Gomez F; Fehniger TA
Blood; 2018 Jan; 131(2):182-190. PubMed ID: 29074501
[TBL] [Abstract][Full Text] [Related]
37. Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma.
Noy A; de Vos S; Thieblemont C; Martin P; Flowers CR; Morschhauser F; Collins GP; Ma S; Coleman M; Peles S; Smith S; Barrientos JC; Smith A; Munneke B; Dimery I; Beaupre DM; Chen R
Blood; 2017 Apr; 129(16):2224-2232. PubMed ID: 28167659
[TBL] [Abstract][Full Text] [Related]
38. Bortezomib enhances the anti-cancer effect of the novel Bruton's tyrosine kinase inhibitor (BGB-3111) in mantle cell lymphoma expressing BTK.
Wang X; Fei Y; Liu X; Zhang T; Li W; Jia X; Liu X; Qiu L; Qian Z; Zhou S; Ren X; Zhai Q; Meng B; Li L; Zhang H
Aging (Albany NY); 2021 Sep; 13(17):21102-21121. PubMed ID: 34508613
[TBL] [Abstract][Full Text] [Related]
39. Ibrutinib in CLL: a focus on adverse events, resistance, and novel approaches beyond ibrutinib.
Kaur V; Swami A
Ann Hematol; 2017 Jul; 96(7):1175-1184. PubMed ID: 28342031
[TBL] [Abstract][Full Text] [Related]
40. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma.
Wang ML; Rule S; Martin P; Goy A; Auer R; Kahl BS; Jurczak W; Advani RH; Romaguera JE; Williams ME; Barrientos JC; Chmielowska E; Radford J; Stilgenbauer S; Dreyling M; Jedrzejczak WW; Johnson P; Spurgeon SE; Li L; Zhang L; Newberry K; Ou Z; Cheng N; Fang B; McGreivy J; Clow F; Buggy JJ; Chang BY; Beaupre DM; Kunkel LA; Blum KA
N Engl J Med; 2013 Aug; 369(6):507-16. PubMed ID: 23782157
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
